ICI-induced colitis shares endoscopic and histological features with inflammatory bowel disease and the treatment of choice is represented by corticosteroids, followed by infliximab (anti-TNFα antibody) and vedolizumab (anti α4β7 integrin antibody) in steroid- and steroid/infliximab–refractory patients, respectively (Som et al, 2019). Here, TNF is linked to colitis.